3 documents found, page 1 of 1
Clinical outcomes and patient-matched molecular composition of relapsed medullo...
Kumar, Rahul; Smith, Kyle S.; Deng, Maximilian; Terhune, Colt; Robinson, Giles W; Orr, Brent A.; Liu, Anthony P. Y.; Lin, Tong; Billups, Catherine A.Purpose: We sought to investigate clinical outcomes of relapsed medulloblastoma and to compare molecular features between patient-matched diagnostic and relapsed tumors. Methods: Children and infants enrolled on either SJMB03 (NCT00085202) or SJYC07 (NCT00602667) trials who experienced medulloblastoma relapse were analyzed for clinical outcomes, including anatomic and temporal patterns of relapse and postrelaps...
Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas
Guerreiro Stucklin, Ana S.; Ryall, Scott; Fukuoka, Kohei; Zapotocky, Michal; Lassaletta, Alvaro; Li, Christopher; Bridge, Taylor; Kim, ByungjinInfant gliomas have paradoxical clinical behavior compared to those in children and adults: low-grade tumors have a higher mortality rate, while high-grade tumors have a better outcome. However, we have little understanding of their biology and therefore cannot explain this behavior nor what constitutes optimal clinical management. Here we report a comprehensive genetic analysis of an international cohort of cl...
A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targ...
Baruchel, Sylvain; Sharp, Julia R.; Bartels, Ute; Hukin, Juliette; Odame, Isaac; Portwine, Carol; Strother, Doug; Fryer, Chris; Reis, R. M.PURPOSE: To evaluate the safety, efficacy and pharmacokinetics of imatinib in children with recurrent or refractory central nervous system (CNS) tumours expressing KIT and/or PDGFRA. METHODS: Nineteen patients aged 2-18 years, with recurrent or refractory CNS tumours expressing either of the target receptors KIT and/or PDGFRA (by immunohistochemistry) were eligible. Participants received imatinib orally at a do...